Selective HDAC6 Inhibitors via Zinc-Binding and Heteroaryl Linkers
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current HDAC inhibitors lack selectivity for HDAC6 over HDAC1, which can lead to off-target effects and reduced therapeutic efficacy in treating conditions affected by HDAC activity.
Innovation Solution
Development of novel compounds with a specific structural formula that selectively inhibit HDAC6 by incorporating a zinc-binding group and heteroaryl capping groups connected via an alkylene linker, allowing for potent and selective modulation of HDAC activity.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current HDAC inhibitors are used, then HDAC activity is inhibited, but selectivity for HDAC6 over HDAC1 is insufficient leading to off-target effects
Solution Approach 1:
The patent applies local quality by introducing specific functional groups at particular positions in the molecule. The zinc-binding group (such as hydroxamic acid, carboxylic acid, or heterocyclic amine) is positioned to specifically interact with HDAC6's zinc ion, while heteroaryl capping groups (such as pyridine, pyrimidine, or triazole rings) are placed to engage with residues unique to HDAC6's binding pocket. This localized functional differentiation enables selective inhibition of HDAC6 over HDAC1.
Solution Approach 2:
The patent employs parameter changes by modifying molecular properties including the length and composition of alkylene linkers (varying carbon chain length), the specific type of zinc-binding group, and the nature of heteroaryl capping groups. These parameter modifications tune the compound's affinity and selectivity for HDAC6, achieving potent inhibition with minimal off-target effects.
2Reliability
If HDAC inhibitors are used to treat conditions affected by HDAC activity, then therapeutic potential is achieved, but off-target effects reduce therapeutic efficacy
Solution Approach 1:
The patent applies local quality by introducing specific functional groups at particular positions in the molecule. The zinc-binding group (such as hydroxamic acid, carboxylic acid, or heterocyclic amine) is positioned to specifically interact with HDAC6's zinc ion, while heteroaryl capping groups (such as pyridine, pyrimidine, or triazole rings) are placed to engage with residues unique to HDAC6's binding pocket. This localized functional differentiation enables selective inhibition of HDAC6 over HDAC1.
Solution Approach 2:
The patent employs parameter changes by modifying molecular properties including the length and composition of alkylene linkers (varying carbon chain length), the specific type of zinc-binding group, and the nature of heteroaryl capping groups. These parameter modifications tune the compound's affinity and selectivity for HDAC6, achieving potent inhibition with minimal off-target effects.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The compounds demonstrate high selectivity for HDAC6 over HDAC1, enhancing therapeutic potential by minimizing off-target effects and improving treatment outcomes for conditions related to HDAC activity.
Implementation Method 1
compounds which are able to modulate HDAC... HDACs are zinc metalloenzymes that catalyse the hydrolysis of acetylated lysine residues
Data Source
AI summary
The present invention is a compound of the formula or a pharmaceutically acceptable salt thereof. The compounds are useful as HDAC inhibitors.